Skip to content

Study on the clinical efficacy of "Sijunzi Decoction" combined with "Xuanbai Chengqi Decoction" on acute gastrointestinal injury (spleen deficiency and qi stagnation syndrome)

Study on the clinical efficacy of "Sijunzi Decoction" combined with "Xuanbai Chengqi Decoction" on acute gastrointestinal injury (spleen deficiency and qi stagnation syndrome)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105069
Enrollment
Unknown
Registered
2025-06-27
Start date
2024-10-14
Completion date
Unknown
Last updated
2025-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Gastrointestinal Injury (AGI)

Interventions

Control group: Routine treatmen
Observation group:Add traditional Chinese medicine decoctions based on routine treatment

Sponsors

Department of Critical Care Medicine, Women and Children's (Sixth People's) Hospital, Fuyang City, Anhui Province
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of AGI Western medicine and the syndrome of spleen deficiency and qi stagnation in traditional Chinese medicine. 2. Full informed consent of the research subject himself or his legal guardian. 3. Can tolerate treatment with traditional Chinese medicine decoction.

Exclusion criteria

Exclusion criteria: 1. It does not meet the diagnostic criteria of AGI Western medicine and the spleen deficiency and qi stagnation syndrome of traditional Chinese medicine. 2. At the time of admission to the ICU, the patient had gastrointestinal perforation, massive gastrointestinal bleeding, intestinal ischemia and necrosis, intestinal fistula, intestinal surgery, intestinal obstruction and other intestinal pathologies 3. Those who are unable to take Chinese medicine for various reasons and give up continuing treatment 4. Do not agree with the treatment of Chinese herbal decoction, or are allergic to Chinese medicine 5. Have gastrointestinal malignancy or end-stage malignancy 6. AGI patients who have been treated for less than 7 days or have given up treatment or died during treatment 7. Failure to implement the intervention as prescribed, and the efficacy cannot be determined. 8. Serious adverse reactions, complications, special physiological changes, etc., which are difficult to continue treatment. 9. Use of other drugs that affect the results of this study. 10. Those who do not have enteral nutrition conditions.

Design outcomes

Primary

MeasureTime frame
Gastrointestinal motility index;Biological indicators of intestinal barrier function impairment;AGI rating, gastrointestinal dysfunction score;Severity and prognosis: APACHE II score, SOFA score, 28d mortality;

Countries

China

Contacts

Public ContactZhou Minghu

Department of Critical Care Medicine, Women and Children's (Sixth People's) Hospital, Fuyang City, Anhui Province

878901186@qq.com+86 558 666 9198

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026